A Phase I-II Study of BIBF 1120 and FOLFOX Compared to Bevacizumab and FOLFOX in First Line Metastatic Colorectal Cancer Patients.
Phase of Trial: Phase II
Latest Information Update: 06 Feb 2015
At a glance
- Drugs Nintedanib (Primary) ; Bevacizumab; Fluorouracil; Folinic acid; Oxaliplatin
- Indications Colorectal cancer
- Focus Therapeutic Use
- Sponsors Boehringer Ingelheim Pharmaceuticals
- 07 Jun 2017 Biomarkers information updated
- 07 Mar 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 27 Sep 2011 The trial is ongoing in order to collect overall survival data, according to a Boehringer Ingelheim media release.